1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity

Autor: Wei Qiu, Qi Sun, Yi Yang, Chirag Patel, Meng Sun, Yue Liu, Kyle Halliwill, Sarah Kim, Rebecca Mathew, Jennifer M Frost, Jennifer A Roth, Domenick Kennedy, Robert T Manguso, Kathleen B Yates, Hakimeh Ebrahimi-Nik, Christina K Baumgartner, Arvin Iracheta-Vellve, Keith M Hamel, Kira Olander, Thomas GR Davis, Kathleen A McGuire, Geoff T Halvorsen, Omar I Avila, Ashwin V Kammula, Audrey J Muscato, Prasanthi Geda, Kelly Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Mitchell D Yeary, James C Patti, Tyler M Balon, Carey Backus, Angeline Chen, Kenton Longenecker, Joseph Klahn, Cara Hrusch, Navasona Krishnan, Charles W Hutchins, Jacqueline Aguado, Marinka Bulic, Payal Tiwari, Kayla J Colvin, Cun Lan Chuong, Ian C Kohnle, Matthew G Rees, Andrew Boghossian, Melissa Ronan, Meng-Ju Wu, Debattama R Sen, Gabriel K Griffin, Nabeel El-Bardeesy, Patricia Trusk, Joshua H Decker, Stacey Fossey, Marcia N Paddock, Elliot P Farney, Clay Beauregard, Philip R Kym

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)

Externí odkaz: https://doaj.org/article/11356ff1bf1f4b63ab1324cafa253315